BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, Wang L, Feng S, Conaghan PG, Berenbaum F, Pelletier J, Martel‐pelletier J, Vaeterlein O, Kaeley GS, Liu W, Kosloski MP, Levy G, Zhang L, Medema JK, Levesque MC. A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol 2019;71:1056-69. [DOI: 10.1002/art.40840] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Kruisbergen NNL, van Gemert Y, Walgreen B, Helsen MMA, Slöetjes AW, Koenders MI, van de Loo FAJ, Roth J, Vogl T, van der Kraan PM, Blom AB, van den Bosch MHJ, van Lent PLEM. A single dose of anti-IL-1β antibodies prevents Western diet-induced immune activation during early stage collagenase-induced osteoarthritis, but does not ameliorate end-stage pathology. Osteoarthritis Cartilage 2021:S1063-4584(21)00842-6. [PMID: 34298196 DOI: 10.1016/j.joca.2021.07.005] [Reference Citation Analysis]
2 Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol 2020;16:673-88. [PMID: 33122845 DOI: 10.1038/s41584-020-00518-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
3 Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol 2019;15:612-32. [DOI: 10.1038/s41584-019-0277-8] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 30.3] [Reference Citation Analysis]
4 Thomson A, Hilkens CMU. Synovial Macrophages in Osteoarthritis: The Key to Understanding Pathogenesis? Front Immunol 2021;12:678757. [PMID: 34211470 DOI: 10.3389/fimmu.2021.678757] [Reference Citation Analysis]
5 Cai X, Yuan S, Zeng Y, Wang C, Yu N, Ding C. New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol 2021;12:645842. [PMID: 33935742 DOI: 10.3389/fphar.2021.645842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Grässel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Res 2020;9:F1000 Faculty Rev-325. [PMID: 32419923 DOI: 10.12688/f1000research.22115.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 14.5] [Reference Citation Analysis]
7 Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. Lancet Rheumatol 2020;2:e633-45. [PMID: 32989436 DOI: 10.1016/S2665-9913(20)30279-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
8 Dainese P, Wyngaert KV, De Mits S, Wittoek R, Van Ginckel A, Calders P. Association between knee inflammation and knee pain in patients with knee osteoarthritis: a systematic review. Osteoarthritis Cartilage 2021:S1063-4584(21)01003-7. [PMID: 34968719 DOI: 10.1016/j.joca.2021.12.003] [Reference Citation Analysis]
9 Wan M, Gray-Gaillard EF, Elisseeff JH. Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration. Bone Res 2021;9:41. [PMID: 34508069 DOI: 10.1038/s41413-021-00164-y] [Reference Citation Analysis]
10 Pham TM, Erichsen JL, Kowal JM, Overgaard S, Schmal H. Elevation of Pro-Inflammatory Cytokine Levels Following Intra-Articular Fractures-A Systematic Review. Cells 2021;10:902. [PMID: 33919965 DOI: 10.3390/cells10040902] [Reference Citation Analysis]
11 Cao Y, Ma Y, Tao Y, Lin W, Wang P. Intra-Articular Drug Delivery for Osteoarthritis Treatment. Pharmaceutics 2021;13:2166. [PMID: 34959445 DOI: 10.3390/pharmaceutics13122166] [Reference Citation Analysis]
12 Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage 2021;29:654-66. [PMID: 33588087 DOI: 10.1016/j.joca.2021.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
13 Cao Z, Li Y, Wang W, Jie S, Hu X, Zhou J, Wu T, Aili D, Long Z, Li Y, Dou P, Wu R. Is Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis. Biomed Res Int 2020;2020:9013283. [PMID: 33204726 DOI: 10.1155/2020/9013283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sandomenico A, Sivaccumar JP, Ruvo M. Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments. Int J Mol Sci 2020;21:E6324. [PMID: 32878291 DOI: 10.3390/ijms21176324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford) 2020;59:2681-94. [PMID: 32691066 DOI: 10.1093/rheumatology/keaa248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
16 König C, Vazquez E, Eß S, Ebbinghaus M, Vorpahl B, Ebersberger A, Schaible HG. Spinal interleukin-1β induces mechanical spinal hyperexcitability in rats: Interactions and redundancies with TNF and IL-6. J Neurochem 2021;158:898-911. [PMID: 34050952 DOI: 10.1111/jnc.15438] [Reference Citation Analysis]
17 Mimpen JY, Snelling SJB. Chondroprotective Factors in Osteoarthritis: a Joint Affair. Curr Rheumatol Rep 2019;21:41. [PMID: 31227927 DOI: 10.1007/s11926-019-0840-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Teo KYW, Sevencan C, Cheow YA, Zhang S, Leong DT, Toh WS. Macrophage Polarization as a Facile Strategy to Enhance Efficacy of Macrophage Membrane‐Coated Nanoparticles in Osteoarthritis. Small Science. [DOI: 10.1002/smsc.202100116] [Reference Citation Analysis]
19 Astrike-Davis EM, Coryell P, Loeser RF. Targeting cellular senescence as a novel treatment for osteoarthritis. Curr Opin Pharmacol 2022;64:102213. [PMID: 35447516 DOI: 10.1016/j.coph.2022.102213] [Reference Citation Analysis]
20 Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen AC, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res 2019;8:F1000 Faculty Rev-2091. [PMID: 31885861 DOI: 10.12688/f1000research.20575.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
21 Ou D, Liu S, Tong C, Tan H, Yang Y, He C. LIM mineralization protein-1 inhibits IL-1β-induced human chondrocytes injury by altering the NF-κB and MAPK/JNK pathways. Exp Ther Med 2022;23:61. [PMID: 34934432 DOI: 10.3892/etm.2021.10983] [Reference Citation Analysis]
22 Eckstein F, Wirth W, Culvenor AG. Osteoarthritis year in review 2020: imaging. Osteoarthritis Cartilage 2021;29:170-9. [PMID: 33418028 DOI: 10.1016/j.joca.2020.12.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Fayd'herbe De Maudave A, Leconet W, Toupet K, Constantinides M, Bossis G, de Toledo M, Vialaret J, Hirtz C, Lopez-Noriega A, Jorgensen C, Noël D, Louis-Plence P, Grizot S, Villalba M. Intra-articular delivery of full-length antibodies through the use of an in situ forming depot. J Control Release 2021;341:578-90. [PMID: 34915070 DOI: 10.1016/j.jconrel.2021.12.010] [Reference Citation Analysis]
24 Hu Y, Chen X, Wang S, Jing Y, Su J. Subchondral bone microenvironment in osteoarthritis and pain. Bone Res 2021;9:20. [PMID: 33731688 DOI: 10.1038/s41413-021-00147-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kahlenberg JM, Kang I. Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases. Arthritis Rheumatol 2020;72:386-95. [PMID: 31562704 DOI: 10.1002/art.41127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
26 Mobasheri A. Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves. NeuroSci 2021;2:45-58. [DOI: 10.3390/neurosci2010003] [Reference Citation Analysis]
27 Aslam F, England BR, Cannella A, Sharp V, Kao L, Arnason J, Albayda J, Bakewell C, Sanghvi S, Fairchild R, Torralba KD, Evangelisto A, DeMarco PJ, Bethina N, Kissin EY. Ultrasound Doppler and tenosynovial fluid analysis in tenosynovitis. Ann Rheum Dis 2020;79:908-13. [PMID: 32213497 DOI: 10.1136/annrheumdis-2020-216927] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Colella F, Garcia JP, Sorbona M, Lolli A, Antunes B, D'Atri D, Barré FPY, Oieni J, Vainieri ML, Zerrillo L, Capar S, Häckel S, Cai Y, Creemers LB. Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents. J Control Release 2020;328:985-99. [PMID: 32860929 DOI: 10.1016/j.jconrel.2020.08.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage 2020;28:242-8. [PMID: 31945457 DOI: 10.1016/j.joca.2020.01.002] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 50.5] [Reference Citation Analysis]
30 Bay-Jensen AC, Bihlet A, Byrjalsen I, Andersen JR, Riis BJ, Christiansen C, Michaelis M, Guehring H, Ladel C, Karsdal MA. Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. Sci Rep 2021;11:6583. [PMID: 33753821 DOI: 10.1038/s41598-021-86064-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Spel L, Martinon F. Inflammasomes contributing to inflammation in arthritis. Immunol Rev 2020;294:48-62. [DOI: 10.1111/imr.12839] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
32 Meng F, Li H, Feng H, Long H, Yang Z, Li J, Wang Y, Xie D. Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210803. [DOI: 10.1177/1759720x221080377] [Reference Citation Analysis]
33 Liu J, Ting JP, Al-Azzam S, Ding Y, Afshar S. Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. Int J Mol Sci 2021;22:2805. [PMID: 33802091 DOI: 10.3390/ijms22062805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Peat G, Thomas MJ. Osteoarthritis year in review 2020: epidemiology & therapy. Osteoarthritis Cartilage 2021;29:180-9. [PMID: 33242603 DOI: 10.1016/j.joca.2020.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Hayashi D, Roemer FW, Eckstein F, Samuels J, Guermazi A. Imaging of OA – From disease modification to clinical utility. Best Practice & Research Clinical Rheumatology 2020;34:101588. [DOI: 10.1016/j.berh.2020.101588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Galozzi P, Bindoli S, Doria A, Sfriso P. The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmun Rev 2021;20:102785. [PMID: 33621698 DOI: 10.1016/j.autrev.2021.102785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Reed KSM, Ulici V, Kim C, Chubinskaya S, Loeser RF, Phanstiel DH. Transcriptional response of human articular chondrocytes treated with fibronectin fragments: an in vitro model of the osteoarthritis phenotype. Osteoarthritis Cartilage 2021;29:235-47. [PMID: 33248223 DOI: 10.1016/j.joca.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Ghouri A, Quicke JG, Conaghan PG. New developments in osteoarthritis pharmacological therapies. Rheumatology (Oxford) 2021;60:vi1-vi11. [PMID: 34951922 DOI: 10.1093/rheumatology/keab679] [Reference Citation Analysis]
39 Logashina YA, Palikova YA, Palikov VA, Kazakov VA, Smolskaya SV, Dyachenko IA, Tarasova NV, Andreev YA. Anti-Inflammatory and Analgesic Effects of TRPV1 Polypeptide Modulator APHC3 in Models of Osteo- and Rheumatoid Arthritis. Mar Drugs 2021;19:39. [PMID: 33477357 DOI: 10.3390/md19010039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Cho Y, Jeong S, Kim H, Kang D, Lee J, Kang SB, Kim JH. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Exp Mol Med 2021;53:1689-96. [PMID: 34848838 DOI: 10.1038/s12276-021-00710-y] [Reference Citation Analysis]
41 Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA 2021;325:568-78. [PMID: 33560326 DOI: 10.1001/jama.2020.22171] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
42 Vrouwe J, Burggraaf J, Kloppenburg M, Stuurman F. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthritis and Cartilage Open 2021;3:100212. [DOI: 10.1016/j.ocarto.2021.100212] [Reference Citation Analysis]
43 Carpintero-fernández P, Varela-eirín M, García-yuste A, López-díaz I, Caeiro JR, Mayán MD. Osteoarthritis: Mechanistic Insights, Senescence, and Novel Therapeutic Opportunities. Bioelectricity. [DOI: 10.1089/bioe.2021.0039] [Reference Citation Analysis]
44 Liu F, Li L, Lan M, Zou T, Kong Z, Cai T, Wu XY, Cai Y. Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling. Mediators Inflamm 2021;2021:7785890. [PMID: 34602858 DOI: 10.1155/2021/7785890] [Reference Citation Analysis]
45 Mohammadi M, Jeddi-Tehrani M, Golsaz-Shirazi F, Arjmand M, Bahadori T, Judaki MA, Shiravi F, Zare HA, Haghighat FN, Mobini M, Amiri MM, Shokri F. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. Front Immunol 2020;11:600883. [PMID: 33679691 DOI: 10.3389/fimmu.2020.600883] [Reference Citation Analysis]
46 Lv Z, Yang YX, Li J, Fei Y, Guo H, Sun Z, Lu J, Xu X, Jiang Q, Ikegawa S, Shi D. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol 2021;9:725568. [PMID: 34513847 DOI: 10.3389/fcell.2021.725568] [Reference Citation Analysis]
47 Coryell PR, Diekman BO, Loeser RF. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol 2021;17:47-57. [PMID: 33208917 DOI: 10.1038/s41584-020-00533-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
48 Theeuwes WF, van den Bosch MHJ, Thurlings RM, Blom AB, van Lent PLEM. The role of inflammation in mesenchymal stromal cell therapy in osteoarthritis, perspectives for post-traumatic osteoarthritis: a review. Rheumatology (Oxford) 2021;60:1042-53. [PMID: 33410465 DOI: 10.1093/rheumatology/keaa910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res 2019;8:F1000 Faculty Rev-934. [PMID: 31249675 DOI: 10.12688/f1000research.18831.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
50 Chadha S, Behl T, Bungau S, Kumar A, Arora R, Gupta A, Uddin MS, Zengin G, Aleya L, Setia D, Arora S. Mechanistic insights into the role of pyroptosis in rheumatoid arthritis. Curr Res Transl Med 2020;68:151-8. [PMID: 32830085 DOI: 10.1016/j.retram.2020.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
51 Oo WM, Little C, Duong V, Hunter DJ. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Des Devel Ther 2021;15:2921-45. [PMID: 34262259 DOI: 10.2147/DDDT.S295224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chevalier X, Eymard F. Anti-IL-1 for the treatment of OA: dead or alive? Nat Rev Rheumatol 2019;15:191-2. [PMID: 30770908 DOI: 10.1038/s41584-019-0185-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
53 Tryfonidou MA, de Vries G, Hennink WE, Creemers LB. "Old Drugs, New Tricks" - Local controlled drug release systems for treatment of degenerative joint disease. Adv Drug Deliv Rev 2020;160:170-85. [PMID: 33122086 DOI: 10.1016/j.addr.2020.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Nurul AA, Azlan M, Ahmad Mohd Zain MR, Sebastian AA, Fan YZ, Fauzi MB. Mesenchymal Stem Cells: Current Concepts in the Management of Inflammation in Osteoarthritis. Biomedicines 2021;9:785. [PMID: 34356849 DOI: 10.3390/biomedicines9070785] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Garcia JP, Utomo L, Rudnik-Jansen I, Du J, Zuithoff NPA, Krouwels A, van Osch GJVM, Creemers LB. Association between Oncostatin M Expression and Inflammatory Phenotype in Experimental Arthritis Models and Osteoarthritis Patients. Cells 2021;10:508. [PMID: 33673583 DOI: 10.3390/cells10030508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Sukhikh S, Babich O, Prosekov A, Patyukov N, Ivanova S. Future of Chondroprotectors in the Treatment of Degenerative Processes of Connective Tissue. Pharmaceuticals (Basel) 2020;13:E220. [PMID: 32872387 DOI: 10.3390/ph13090220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
57 Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Ann Med Surg (Lond) 2021;72:103077. [PMID: 34868573 DOI: 10.1016/j.amsu.2021.103077] [Reference Citation Analysis]
58 Löhning M, Shen P, Dzamukova M, Durán-Hernández N, Roodselaar J, Hauser AE, Fiedler A, Niesner RA, Gaber T, Buttgereit F. [The DRFZ-a pioneer in research on the interaction between immune and stromal cells during de- and regeneration of the musculoskeletal system]. Z Rheumatol 2022. [PMID: 35412048 DOI: 10.1007/s00393-022-01188-3] [Reference Citation Analysis]
59 Maksymowych WP, McReynolds A, Pedersen SJ, Weber U, Paschke J, Wichuk S, Jaremko JL, Lambert RG. The OMERACT Knee Inflammation MRI Scoring System: Validation of quantitative methodologies and tri-compartmental overlays in osteoarthritis. Semin Arthritis Rheum 2021;51:925-8. [PMID: 34167825 DOI: 10.1016/j.semarthrit.2021.05.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ana-maria P, Simona F, Mihaela GC, Elena LC. New Molecular Targets in the Therapy of Arthrosis Patients. ARS Medica Tomitana 2019;25:120-4. [DOI: 10.2478/arsm-2019-0024] [Reference Citation Analysis]
61 Au M, Liu Z, Rong L, Zheng Y, Wen C. Endothelin-1 induces chondrocyte senescence and cartilage damage via endothelin receptor type B in a post-traumatic osteoarthritis mouse model. Osteoarthritis Cartilage 2020;28:1559-71. [PMID: 32858189 DOI: 10.1016/j.joca.2020.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res 2019;8:F1000 Faculty Rev-1549. [PMID: 31508202 DOI: 10.12688/f1000research.18688.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
63 Ummarino A, Gambaro FM, Kon E, Torres Andón F. Therapeutic Manipulation of Macrophages Using Nanotechnological Approaches for the Treatment of Osteoarthritis. Nanomaterials (Basel) 2020;10:E1562. [PMID: 32784839 DOI: 10.3390/nano10081562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
64 Ragni E, Mangiavini L, Viganò M, Brini AT, Peretti GM, Banfi G, de Girolamo L. Management of Osteoarthritis During the COVID-19 Pandemic. Clin Pharmacol Ther 2020;108:719-29. [PMID: 32438454 DOI: 10.1002/cpt.1910] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
65 Kloppenburg M, Levesque M. Response to: 'Can IL-1 be used as a target for osteoarthritis?' by Cheng et al. Ann Rheum Dis 2020;79:e89. [PMID: 31248854 DOI: 10.1136/annrheumdis-2019-215612] [Reference Citation Analysis]
66 Li Z, Dai A, Yang M, Chen S, Deng Z, Li L. p38MAPK Signaling Pathway in Osteoarthritis: Pathological and Therapeutic Aspects. JIR 2022;Volume 15:723-34. [DOI: 10.2147/jir.s348491] [Reference Citation Analysis]
67 Bohaud C, Contreras-Lopez R, De La Cruz J, Terraza-Aguirre C, Wei M, Djouad F, Jorgensen C. Pro-regenerative Dialogue Between Macrophages and Mesenchymal Stem/Stromal Cells in Osteoarthritis. Front Cell Dev Biol 2021;9:718938. [PMID: 34604219 DOI: 10.3389/fcell.2021.718938] [Reference Citation Analysis]
68 Oo WM. Prospects of Disease-Modifying Osteoarthritis Drugs. Clinics in Geriatric Medicine 2022;38:397-432. [DOI: 10.1016/j.cger.2021.11.010] [Reference Citation Analysis]
69 Du Y, Xu J. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Adv Mater 2021;:e2103114. [PMID: 34585802 DOI: 10.1002/adma.202103114] [Reference Citation Analysis]
70 Olmos Calvo I, Fodor E, Kardos D, Hornyák I, Hinsenkamp A, Kuten-Pella O, Gyevnár Z, Erdélyi G, Bárdos T, Paukovits TM, Magos K, Béres G, Nehrer S, Lacza Z. A Pilot Clinical Study of Hyperacute Serum Treatment in Osteoarthritic Knee Joint: Cytokine Changes and Clinical Effects. Curr Issues Mol Biol 2021;43:637-49. [PMID: 34287260 DOI: 10.3390/cimb43020046] [Reference Citation Analysis]
71 Zhao Q. Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date. BioDrugs 2020;34:111-9. [DOI: 10.1007/s40259-019-00400-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]